



Cite this: *Lab Chip*, 2020, 20, 3187

Label-free ferrohydrodynamic separation of exosome-like nanoparticles†

Yang Liu,^a Wujun Zhao,^a Rui Cheng,^b Meghan Logun,^{cd} Maria del Mar Zayas-Viera,^e Lohitash Karumbaiah^{cdf} and Leidong Mao^{id}*^b

Isolation of exosomes from biological samples provides a minimally-invasive alternative for basic understanding, diagnosis, and prognosis of metastatic cancers. The biology and clinical values of exosomes are under intensive investigation, yet most studies are limited by technical challenges in recovering these exosomes with heterogeneous sizes and cargos from biological samples. We report a novel method based on “particle ferrohydrodynamics” and its associated microfluidic device, termed as the FerroChip, which can separate exosome-like nanoparticles from microliters of cell culture media and human serum in a label-free, continuous-flow and size-dependent manner, and achieves a high recovery rate (94.3%) and a high purity (87.9%). Separated exosome-like nanoparticles had diameters, morphology, and protein expressions that were consistent with other reports. This method, upon further molecular characterization, could potentially facilitate basic understanding of exosomes and its clinical application in blood liquid biopsy.

Received 12th June 2020,
Accepted 21st July 2020

DOI: 10.1039/d0lc00609b

rsc.li/loc

Introduction

Progress on understanding the communication between tumor cells and their microenvironments are crucial for the development of new diagnostic methods and therapeutic strategies.^{1–3} Such communication, traditionally known to occur through direct cell–cell contacts and soluble factor secreted by tumor cells, is now revealed to have an additional mechanism involving extracellular vesicles (EVs).^{4,5} EVs consist of a heterogeneous population of lipid-encapsulated vesicles that transmit functional proteins and nucleic acids, with multiple subtypes including exosomes that are extracellular membrane vesicles of endosomal origin, having a physical diameter typically within the range of 30–150 nm.^{4–7} Other subtypes of EVs include microvesicles that are shed directly by budding from the cellular plasma membrane, with a physical diameter ranges from 100–1000 nm.^{4–7}

Growing evidence shows that EVs participate in the metastatic spreading of cancers, in which tumor-derived EVs aid the establishment of pre-metastatic niche and facilitates tumor progression.^{8–13} As a result, circulating tumor exosomes containing tumor-specific molecular messages could hold promising clinical utilities as next-generation diagnostic and prognostic biomarkers in liquid biopsy.^{4,8,9}

Despite the rapid progress in the understanding of the biology, function, and clinical utilities of extracellular vesicles, the heterogeneous sizes and cargos of these nanoscale vesicles and the technical limitations in separating pure exosomal subpopulation have hindered the characterization of their molecular signatures and its clinical utility. Various strategies have been developed to isolate EV subpopulations, especially exosomes. These strategies include benchtop methods that rely on either differential ultracentrifugation or polymer-based precipitation. Even though these methods can handle milliliters to liters of samples, the recovery rate, purity, and integrity of separated exosomes, as well as their labor-intensiveness and long processing time remain to be improved.⁶ Microfluidic methods emerged as a promising alternative to the benchtop methods in separating exosomes in microliters to milliliters of samples, with high purity or recovery rate while keeping the cost affordable and the processing time short. Technologies of microfluidic exosome separation can be divided into two categories, with the label-based ones relying on surface markers of exosomes for selective separation of specific exosomal subpopulations with high purity.^{14–20} On the other hand, label-free separation

^a Department of Chemistry, The University of Georgia, Athens, GA 30602, USA

^b School of Electrical and Computer Engineering, The University of Georgia, Athens, GA 30602, USA. E-mail: mao@uga.edu

^c Regenerative Bioscience Center, University of Georgia, Athens, GA 30602, USA

^d Division of Neuroscience, Biomedical Health Sciences Institute, University of Georgia, Athens, GA 30602, USA

^e Department of Chemical Engineering, University of Puerto Rico-Mayaguez, Mayaguez, PR 00681, USA

^f Edgar L. Rhodes Center for Animal and Dairy Science, College of Agriculture and Environmental Sciences, University of Georgia, Athens, GA 30602, USA

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0lc00609b

explores the size difference between exosomes and other EVs, including deterministic lateral displacement,²¹ pinched-flow fractionation,²² asymmetric-flow field-flow fractionation,²³ filtration,^{24–28} nanowire trapping,^{29,30} viscoelastic separation,³¹ and acoustic separation.³² Label-free separation of exosomes was not biased by the use of specific biomarkers and therefore could lead to exosome separation with high recovery rate. In this paper, we report a new label-free ferrohydrodynamic method for high recovery and purity separation of exosome-like nanoparticles, which are defined as having diameters of 30–150 nm, and morphology and protein expressions consistent with exosomes. This method relies on the physical principle of “particle ferrohydrodynamics” and can separate exosome-like nanoparticles from biological samples with a 94.3% recovery rate and 87.9% purity.

Ferrohydrodynamics describes the mechanics and motion of a magnetizable liquid (e.g., ferrofluids) influenced by strong forces of magnetic polarization.³³ In the context of this paper, we explore “particle ferrohydrodynamics” that refers to the mechanics and motion of an immersed diamagnetic object (either a solid particle or an extracellular vesicle) with close to zero magnetic susceptibility in a magnetizable liquid under an externally applied magnetic field. Particle ferrohydrodynamics is a physical process that drives the immersed object's movement as a result of the interaction between the magnetic field and the magnetic liquid surrounding the object. The magnetic liquid itself, often a ferrofluid, consists of a colloiddally stable suspension of magnetic nanoparticles. Under a non-uniform magnetic field, these magnetic nanoparticles exhibit a gradient of particle concentration while maintaining its stability against irreversible agglomeration thanks to the surfactants on their surfaces. In the particle ferrohydrodynamic process, the magnetic nanoparticles within a ferrofluid continuously collide with the immersed diamagnetic object and generate pressure across the object's surface. This leads to an imbalance of pressure across the object's surface, and a net movement of the object in the opposite direction of nanoparticle concentration, as well as the magnetic field gradient. This phenomenon of an immersed diamagnetic object moving in the opposite direction of the magnetic field gradient is referred to as “diamagnetophoresis” or “negative magnetophoresis” in the literature.³⁴ Particle ferrohydrodynamics was applied in microfluidic systems for micron-sized particle and cellular manipulation, such as isolating extremely rare circulating tumor cells from cancer patients' blood.^{35,36} However, ferrohydrodynamic particle manipulation was thought to be limited to micron-sized objects, because the carrier magnetic liquid consists of nanoparticles with a diameter of ~10 nm. It was thought that the size of the immersed object needed to be significantly larger than the magnetic nanoparticles themselves. Indeed, the smallest objects that were experimentally manipulated in ferrofluids to date was limited to 1 μm , such as polymer particles of 1 μm in diameter,³⁷ and *Escherichia coli* cells with

the short axis of 0.5–1 μm and the long axis of 2–4 μm .³⁸ In this paper, we successfully demonstrated a label-free ferrohydrodynamic method that can separate exosome-like particles with diameters of 30–150 nm from biological samples. To the best of our knowledge, this is the first time that nanosized particles were separated *via* “particle ferrohydrodynamics” in microfluidic devices.

The rest of the paper is structured as follows. We first calculated the theoretical limit of the smallest particles that could be manipulated *via* particle ferrohydrodynamics, and determined the feasibility of applying particle ferrohydrodynamics in microfluidic setting for exosomal separation. We then developed a prototype device termed as the FerroChip, performed systematic optimization of key factors influencing the performance of the FerroChip, and determined parameters for high purity and recovery rate exosomal separation. Finally, we challenged the FerroChip with both cell culture media and human serum for its ability to separate exosome-like nanoparticles.

Results and discussion

Ferrohydrodynamic nanoparticle manipulation

We estimate the smallest nanoparticle that can be ferrohydrodynamically manipulated by comparing quasi-static effects originated from thermal diffusion and ferrohydrodynamic motion, assuming that (1) ferrofluids are a continuous magnetic medium without significant phase separation under an externally applied magnetic field, and (2) the concentration of ferrofluids is small enough so that interparticle interaction can be neglected (Fig. 1a). Ferrofluids at room temperature are colloidal suspensions of magnetic nanoparticles that are stable against externally applied magnetic fields because the magnetic nanoparticles are on the order of 10 nm in diameter. Ferrofluids used in this study had a volume fraction of magnetic materials of 0.3%, therefore they could be considered non-interacting. The theoretical estimate considers a one-dimensional case with a ferrofluid suspension of height L , and immersed particles uniformly dispersed along with L . The characteristic time of an immersed diamagnetic object migrating across L is determined by the shorter of either diffusive time τ_D or ferrohydrodynamic migration time τ_M . The diffusion time of the immersed object in ferrofluids is $\tau_D = L^2/2D$, where $D = \frac{k_B T}{3\pi\eta d}$ is the diffusion coefficient, d is diamagnetic object's diameter, η is ferrofluid viscosity, T is temperature, and k_B is Boltzmann constant. Ferrohydrodynamic migration time of the same diamagnetic object is determined by the Stokes velocity through solving $3\pi\eta d v_M + F_M = 0$, where $F_M = -\mu_0 V (M \cdot \nabla) H$ is ferrohydrodynamic force acting on the particle, μ_0 is permeability of free space, V is object's volume, M is non-linear magnetization of the dilute ferrofluid that is typically modeled through a Langevin function, and H is magnetic field strength at the center of the particle. This yields a characteristic time associated with




Fig. 1 Overview of the label-free ferrohydrodynamic nanoparticle separation principle and the FerroChip device design. **a** (top panel) Schematic of an extracellular vesicle (EV, 30–1000 nm in diameter) experiencing both diffusion and “particle ferrohydrodynamics” in a colloidally-stable magnetic nanoparticle (~10 nm particle diameter) suspension (*i.e.*, ferrofluids). The magnetization of the unlabeled EV M_{EV} is near zero and much less than its surrounding ferrofluids $M_{ferrofluid}$. The ferrohydrodynamic force on the EV is generated from magnetic nanoparticle-induced pressure imbalance on the vesicle’s surface, which is proportional to the EV’s volume. The color bar indicates the relative amplitude of the magnetic field strength. Red arrows show the direction of vesicle movement, small black arrows on the EV’s surface show the direction of magnetic nanoparticle-induced surface pressure. (bottom panel) The relationship between characteristic migration time of a diamagnetic nanoparticle in ferrofluids and the diameter of the nanoparticle. The migration of nanoparticles is affected by both diffusion and “particle ferrohydrodynamics”, and determined by the faster process out of the two. For nanoparticles with a diameter of less than ~30 nm, the diffusive process dominates the migration; for nanoparticles with a diameter of larger than ~30 nm, the ferrohydrodynamic process dominates the migration. **b** Work principle of a label-free continuous-flow EV focusing/separation device, termed as FerroChip. In the focusing mode of device operation, samples of EVs were premixed with a dilute ferrofluid and entered a straight microchannel at a relatively slow flow rate and with a uniform distribution across the channel width. A symmetric magnetic field with its minimum in the middle of the microchannel was used to direct EVs towards the center of the microchannel, effectively focusing them into a narrow stream. In the separation mode, EVs entered the channel predominately through the regions close to the channel wall due to a sheath flow, with a relatively fast flow rate. The same magnetic field was used to direct unlabeled EVs from the sidewall region towards the channel center for continuous collection. EVs of various sizes migrated towards the center of the microchannel, with varying speeds that depended on their sizes. Large EVs migrated to the channel center at a faster speed than smaller exosomes. Yellow arrows with gradients indicate the distribution of magnetic fields in the microchannel. **c** Top-view schematic drawing of the FerroChip’s microchannel. Initial samples of nanoparticles and/or EVs were injected into the channel from inlet 1. The samples, after first going through a debris filter that removed large debris, entered a straight channel (labeled as focusing/separation region) which focused or separated nanoparticles and/or EVs based on their sizes. Processed samples were collected from middle and side outlets for characterizations. When the FerroChip operates in focusing mode, inlet 2 (sheath flow) is not used. When the FerroChip operates in separation mode, inlet 2 provides a ferrofluid sheath flow so that nanoparticles and/or EVs entered from the top and bottom walls of the channel. The width, height and length of the microchannel are 1200 μm , 150 μm and 53 mm, respectively. **d** A photo of a microchannel (left, blue ink indicating the channel geometry) and assembled FerroChip with four permanent magnets in quadrupole configuration inside a holder (right). The microfluidic device and permanent magnets were placed within an aluminum manifold during its operation. Scale bars: 1 cm.

ferrohydrodynamic motion $\tau_M = l \times L/D$, where $l = \frac{k_B T}{F_M}$ has the dimension of length and is indicative of the spatial scale of ferrohydrodynamic migration. The total characteristic time

τ of the diamagnetic object migrating across length L is thus $\tau = \frac{\tau_D \times \tau_M}{\tau_D + \tau_M}$. The faster process, whether it is diffusive or ferrohydrodynamic, decides the actual time τ . When $\tau_D = \tau_M$,

one obtains the critical diameter of the diamagnetic object that experiences both diffusion and ferrohydrodynamic migration equally, which is $d = \left(\frac{12k_B T}{\pi \mu_0 L M \nabla H} \right)^{\frac{1}{3}}$.

Fig. 1a shows that this critical diameter at room temperature (23 °C) is ~ 30 nm, calculated from relevant parameters in a typical microfluidic setting, including a migration distance $L = 500$ μm , a ferrofluid magnetization $M = \sim 1100$ A m^{-1} , corresponding to the 0.3% (v/v) maghemite particle based ferrofluid used in this study, and a gradient of magnetic field strength $\nabla H = \sim 8 \times 10^8$ A m^{-2} , corresponding to a gradient of flux density $\nabla B = 1000$ T m^{-1} . However, Fig. 1a shows that for a diamagnetic nanoparticle of 30 nm diameter to migrate across 500 μm distance, the estimated characteristic time would be unrealistically long (on the order of 10^4 seconds) in a microfluidic device. On the other hand, when the nanoparticle diameter increases to ~ 100 nm, ferrohydrodynamic motion becomes a much faster process than diffusion, leading to a significant reduction of the characteristic time to the order of $\sim 10^1$ – 10^2 seconds, making it feasible to manipulate them in microfluidic devices. These theoretical estimates of nanoparticle sizes and characteristic times in particle ferrohydrodynamics, taken together with the constraints from the operation of microfluidic devices, demonstrates that it is possible to ferrohydrodynamically separate diamagnetic nanoparticles that have diameters in the range of 100–1000 nm, and also offers guidance on designing optimal microfluidic devices for this purpose.

Overview of FerroChip design and operation

We designed a microfluidic device, termed as FerroChip, which incorporated the particle ferrohydrodynamic working principle to effectively either focus or separate diamagnetic nanoparticles based on their size alone. Fig. 1b illustrates the device design of a prototype FerroChip. In the focusing mode of device operation (Fig. 1b, top panel), samples of either diamagnetic nanoparticles or extracellular vesicles (EVs) are premixed with a dilute ferrofluid and enter a straight microchannel with a uniform distribution across the channel width. The magnetic fields from a quadrupole array of permanent magnets, the flow velocity of the nanoparticles or EVs, together with the concentration of the ferrofluid, are chosen so that the diamagnetic nanoparticles or EVs will ferrohydrodynamically migrate towards the center of the microchannel regardless of their sizes, effectively focusing all of them into a narrow stream. In the separation mode of operation (Fig. 1b, bottom panel), premixed samples of diamagnetic nanoparticles or EVs with ferrofluids enter the straight microchannel through predominately the regions close to the channel wall, due to the effect of a ferrofluid sheath flow. The magnetic fields, and the flow velocity of the nanoparticles or EVs, together with the concentration of the ferrofluid, are chosen so that the ferrohydrodynamic migration of nanoparticles or EVs towards the center of the microchannel depends on their sizes. Larger diamagnetic

nanoparticles or EVs migrate with a faster speed while smaller ones with a slower speed, resulting in a spatial separation of the differently sized objects at the outlets of the channel. Fig. 1c and d show the prototype microchannel that is capable of both nanoparticles and EVs focusing and separation and an assembled FerroChip in use.

The theoretical estimate of size-dependent characteristic time presented in the previous section has provided a framework for understanding the dominant effects in particle ferrohydrodynamics. Ferrohydrodynamic motion of particles becomes the dominant effect at room temperature as the diameter of particles exceeds ~ 100 nm. With the FerroChip, we intended to apply the particle ferrohydrodynamic principle to focus or separate diamagnetic nanoparticles or EVs in ferrofluids. For that purpose, we characterized the performance of the FerroChip using three metrics, including the nanoparticle/EV-processing throughput, nanoparticle/EV recovery rate, nanoparticle/EV purity after processing, which were consistently used and reported in evaluating exosome isolation techniques.^{6,39} For the FerroChip, the parameters affecting these three metrics include device geometry, magnetic field, and its gradient, sample flow rates, and ferrofluid properties. These parameters were coupled and needed to be optimized systematically. Hence, we developed a physical model that takes into consideration the effects of particle ferrohydrodynamics in microfluidic settings, which allowed us to optimize relevant device geometries and operating parameters. This physical model predicted three-dimensional (3D) trajectories of diamagnetic nanoparticles or EVs under laminar flow conditions inside a microchannel. Ferrohydrodynamic force and hydrodynamic drag force were considered in simulating the particle trajectories. In our simulation, we chose to neglect the diffusive effect because the diffusive effect starts to become weaker than the ferrohydrodynamic effect when the diamagnetic particle diameter exceeded ~ 30 nm (Fig. 1a). For instance, the diffusive time is ~ 36 times longer than the ferrohydrodynamic migration time for a diamagnetic particle of 100 nm in diameter. Because the diameter range of the diamagnetic particles in this study is 30–1000 nm, we can neglect the diffusive effect in our model while still simulate the particle migration accurately. This model provided analytical and quick design optimization to determine the above-mentioned variables and parameters depending on the design constraints.

Validation of ferrohydrodynamic motion through nanoparticles focusing

We first validated the ferrohydrodynamic manipulation in the FerroChip through focusing nanoparticles of diameters ranging from 100 nm to 1000 nm, with a goal of understanding the size-dependence of ferrohydrodynamic particle migration at relevant sample flow rates (1–10 μL per minute). The range of sample flow rates represents typically reported data from existing microfluidic EVs separation technologies.^{6,39} The range of particle diameters (100–1000

nm) coincides with major populations of EVs that include microvesicles (100–1000 nm) and exosomes (30–150 nm).^{5–7}

Validation focused on the effects of device geometry, magnetic field, and its gradient, sample flow rates, as well as ferrofluid concentration on the effect of diamagnetic nanoparticle focusing. Firstly, we determined the dimension of focusing region of the microchannel by balancing a need of processing $\sim 100\ \mu\text{L}$ of EVs sample within one hour, and a need to maintain laminar flow in the device. Final microchannel dimensions ($55 \times 1.2 \times 0.15\ \text{mm}$, $L \times W \times H$) were optimized so that Reynold's number was on the order of 0.03 when the sample flow rate was $100\ \mu\text{L h}^{-1}$, ensuring laminar flow condition. The prototype microchannel is shown in Fig. 1c. Secondly, the amplitude of ferrohydrodynamic force on diamagnetic nanoparticles is proportional to the amplitude of the magnetic field gradient. In order to maximize the field gradient, we adopted a quadrupole magnet configuration in the FerroChip design that could be optimized to generate the needed magnetic flux density and its gradient. Using four

permanent magnets (38.1 mm by 6.35 mm by 6.35 mm, N52 neodymium magnet) in a quadrupole configuration shown in Fig. 2a, a magnetic flux density of up to 0.5 T in the x - y plane ($z = 0$), and a magnetic flux density gradient of $1272\ \text{T m}^{-1}$ in the y - z plane ($x = 0$) were obtained. Under the magnetic field of the quadrupole magnets, simulation of trajectories of 520 nm polystyrene particles in ferrofluids was conducted to study the effectiveness of FerroChip in focusing these particles. A sample inlet flow rate of $3\ \mu\text{L min}^{-1}$ and a ferrofluid concentration of 0.3% (v/v) were used in the simulation. Results in Fig. 2a show that 520 nm particles could be focused in all three dimensions in the prototype device. Experimental results in Fig. 2b confirmed that ferrohydrodynamic effects under this quadrupole magnet configuration were significant enough so that 520 nm particles were successfully focused into a narrow stream in the FerroChip.

The remaining study explored the effect of sample flow rates and ferrofluid concentration on the focusing effect. We defined an output – the width of focused diamagnetic particle streams




Fig. 2 System optimizations of the FerroChip for continuous-flow nanoparticle focusing. **a** Optimization of high magnetic flux densities and high magnetic flux density gradients in the FerroChip for nanoparticle focusing. Using four permanent magnets (38.1 mm by 6.35 mm by 6.35 mm, N52 neodymium magnet) in a quadrupole configuration shown here, a magnetic flux density of up to 0.5 T in the x - y plane ($z = 0$), and a magnetic flux density gradient of $1272\ \text{T m}^{-1}$ in the y - z plane ($x = 0$) were obtained. Under the magnetic field of the quadrupole magnets, simulation of submicron particle trajectories for 520 nm polystyrene beads in ferrofluids in x - y plane (left), x - z plane (middle), and y - z plane (right), were conducted to study the effectiveness of FerroChip in focusing 520 nm diamagnetic beads. A sample inlet flow rate of $3\ \mu\text{L min}^{-1}$ and a ferrofluid concentration of 0.3% (v/v) were used in the simulation. Results show that 520 nm beads could be focused in all three dimensions in the prototype device. Triangles in the trajectory plots indicate the starting points of particles. **b** (Left panel) Experimental bright-field images show that 520 nm diamagnetic polystyrene beads inside a microchannel can be focused into a narrow stream in the presence of the ferrofluid and quadrupole magnets, using optimized parameters from **a**. (Right panel) Experimental fluorescence images confirm the focusing effects on 520 nm polystyrene. A sample inlet flow rate of $3\ \mu\text{L min}^{-1}$ and a ferrofluid concentration of 0.3% (v/v) were used in **b**. Scale bar: 200 μm .




Fig. 3 Optimizations of nanoparticle focusing in the FerroChip, with parameters including particle diameter, flow rate, and ferrofluid concentration. **a** Optimizations of nanoparticles focusing with parameters including nanoparticle diameters and flow rates through both simulations and experiments. Simulation results agreed with experimental results reasonably well. Both confirmed that the ferrohydrodynamic focusing effect on nanoparticles depended on the diameters of particles in ferrofluids. As the particle size increased, the focusing effect became more pronounced. Additionally, as the flow rates in the microchannel increased, the focusing effect decreased. Particle stream width of the y-axis label indicates the width of the focused particle stream. Orange color shaded area indicates the width of the collection outlet in the FerroChip. A panel of fluorescent images captured during the focusing of 100 nm, 380 nm, 520 nm, and 1000 nm polystyrene beads at a flow rate of $5 \mu\text{L min}^{-1}$ illustrates that focusing effect depended on particle sizes. **b** Optimizations of nanoparticles focusing with the parameter of ferrofluid concentration through both simulations and experiments. Simulation results agreed with experimental results reasonably well. Both confirm that the ferrohydrodynamic focusing effect on submicron beads depended on the ferrofluid concentration. As the ferrofluid concentration increased, the focusing effect became more pronounced. A panel of fluorescent images captured during the focusing of 520 nm polystyrene beads at 0.05%, 0.1%, 0.2% and 0.3% (v/v) ferrofluid concentration illustrates that focusing effect depended on ferrofluid concentrations. Flow rate was $5 \mu\text{L min}^{-1}$. Scale bar is $200 \mu\text{m}$ in all images.

(see Fig. 2a for coordinates) as a way to quantify the focusing effect. This output was optimized using parameters including sample flow rates ($1\text{--}30 \mu\text{L min}^{-1}$) and ferrofluid concentrations ($0\text{--}0.4\%$ v/v). The goal was to maximize the focusing effects, which translated to minimizing the stream width. Fig. 3a shows that simulation and experimental data agreed reasonably well, and both of which indicated that the stream widths had a monotonic relationship with the flow rates. Faster flow rates reduced the residual time of diamagnetic nanoparticles in the microchannel, thereby decreasing the ferrohydrodynamic migration of the particles, which in turn increased the particle stream width. As the size of diamagnetic nanoparticle increased,

the width of stream decreased, due to the fact that ferrohydrodynamic force is proportional to the volume of diamagnetic particles. We further optimized the ferrofluid concentration and found that a higher concentration could lead to a higher magnitude of the diamagnetic force on nanoparticles therefore a larger focusing effect (Fig. 3b).

Optimization of FerroChip for exosome-like nanoparticles separation

We then optimized FerroChip design and its operating parameters for label-free separation of exosomes in biological

fluids, with a goal of isolating exosomes based on their size differences from large extracellular vesicles. The range of diameters of exosomes (30–150 nm) was reported to be smaller than that of apoptotic bodies (>1000 nm) and microvesicles (100–1000 nm).^{5–7} We aimed to exploit this size difference between exosomes and other extracellular vesicles for a high recovery rate and purity separation of exosomes with a clinically relevant throughput. In quantitative terms, the performance goals for the FerroChip included: (1) an exosome recovery rate of >90%; (2) a sample processing throughput of $\sim 1 \mu\text{L min}^{-1}$, and (3) a purity of exosome of >90% after separation. These metrics were chosen as performance targets after a survey of existing microfluidic exosome separation methods (see Table 2).^{6,39}

Through the optimization of FerroChip design and its operating parameters in the previous section, we determined the following parameters that were appropriate for exosome separation. (1) FerroChip device geometry and dimensions: the top view of the device is depicted in Fig. 1c, with optimized channel dimensions ($55 \times 1.2 \times 0.15 \text{ mm}$, $L \times W \times H$) for laminar flow condition and clinically relevant throughput. (2) Magnetic field parameters: a magnetic flux density of up to 0.5 T, and a magnetic flux density gradient of up to 1272 T m^{-1} were achieved *via* assembling four neodymium permanent magnets in quadrupole configuration. (3) Ferrofluid concentration: a 0.3% volume fraction of maghemite nanoparticle based ferrofluid was used. The corresponding viscosity of this ferrofluids was 1.68 mPa s at 23 °C. (4) Sample flow rates: exosomes were represented by 200 nm particle and other larger extracellular vesicles were represented by 1000 nm particles. The mean diameter of exosomes was chosen to be slightly larger than 150 nm to ensure all particles smaller than 200 nm to be separated from larger extracellular vesicles. With these two diameters, we determined through simulations that a sample flow rate of $3 \mu\text{L per minute}$, and a sheath flow rate of $15 \mu\text{L per minute}$, would yield significant separation of the two species in the FerroChip (Fig. 4a). For the simulations, we

calculated two outputs – a deflection in the *y*-direction for EVs (see Fig. 2a for coordinates), denoted as *Y*, and a separation distance between exosome (200 nm) and large EVs (1000 nm), denoted as ΔY . Both outputs were optimized using a sample flow rate of $(0\text{--}10 \mu\text{L min}^{-1})$, *i.e.*, $(0\text{--}600 \mu\text{L h}^{-1})$. The goal was to maximize the exosome recovery rate and minimize large EV contamination, which translated to maximizing ΔY and the flow rate simultaneously. Fig. 4a shows that separation distance ΔY was close to the maximum when using a ferrofluid with 0.3% magnetic volume fraction, and a flow rate of $3 \mu\text{L min}^{-1}$ (*i.e.*, $180 \mu\text{L h}^{-1}$). Fig. 4a also shows a distribution of simulated EV locations at the outlets. The distribution confirms that 200 nm exosomes and 1000 nm large EVs can be ferrohydrodynamically separated in the FerroChip, and 100% of exosomes can be recovered with none of the large EV contamination.

Using optimized device geometry and operating parameters, we studied FerroChip's performance in separating 200 nm diamagnetic nanoparticles from a mixture of 200 nm and 1000 nm particles. A typical separation process can be visualized in Fig. 4b, in which premixed blue fluorescent 200 nm diamagnetic particles and red fluorescent 1000 nm diamagnetic particles with 1 to 1 ratio were processed in a FerroChip device at a sample flow rate of $3 \mu\text{L min}^{-1}$ and a sheath flow rate of $15 \mu\text{L min}^{-1}$. Fluorescent images from the separation process show that before ferrohydrodynamic separation, both 200 nm and 1000 nm particles were mixed and remained close to the sidewall of the microchannel (observation windows 1, 2, and 3 in Fig. 4b). After ferrohydrodynamic separation, blue 200 nm particles migrated slightly away from the sidewall due to a weak ferrohydrodynamic effect on them and exited the channel through the side outlets. On the other hand, red 1000 nm particles experienced a significantly larger ferrohydrodynamic effect and migrated to the center of the channel and exited through the middle outlet (observation windows 4 and 5 in Fig. 4b). This experimental result matched the simulation result in Fig. 4a very well. From the fluorescent image analysis, we confirmed that 200 nm particles could be recovered at 100% recovery rate from the side outlets, and the purity of 200 nm particles from the side outlets were 100% as none of the larger 1000 nm particles exited through side outlets. We further confirmed this result by collecting samples from FerroChip outlets and characterized their particle size distribution using dynamic light scattering (DLS). Fig. 4c shows that particle sample from the FerroChip inlet was a mixture of 200 nm and 1000 nm particles; sample collected from the side outlet were exclusively 200 nm particles; sample collected from the middle outlet were exclusively 1000 nm particles. We note that maghemite particles in ferrofluids appeared in inlets and outlets too. The mean diameters of maghemite particles ($\sim 100 \text{ nm}$) from these spectra were larger than individual maghemite particles ($\sim 10 \text{ nm}$), likely due to particle agglomeration induced by the dilution process that disrupted the surfactant concentration. Additional simulation and experimental data of 200 nm and 520 nm diamagnetic particles in the ESI† (Fig. S1)

Table 1 Summary of recovery rate and purity of exosome-like particles separated from MDA-MB-231 breast cancer cell culture media using the FerroChip. Atomic force microscopy characterization used a maximum ferret diameter of 150 nm to differentiate exosome-like particles and large extracellular vesicles, *i.e.*, diameter of exosome-like particles is less than 150 nm, while diameter of large extracellular vesicles is larger than 150 nm. Super-resolution microscopy characterization used two different fluorescent colors to differentiate exosome-like particles and large extracellular vesicles. Recovery rate is defined as the number of exosome-like particles found in the side outlets over exosome-like particles found in all outlets of the FerroChip. Purity is defined as the number of exosome-like particles found in the side outlets over the sum of exosomes-like particles and large extracellular vesicles found in the side outlets of the FerroChip

Method	Recovery rate	Purity
AFM ($n = 1581$)	96.0%	84.7%
Super-resolution microscopy ($n = 730$)	92.6%	91.1%
Average of the above two methods	94.3%	87.9%

Table 2 A survey of existing microfluidic exosome separation methods

Type	Methods	Throughput	Recovery rate of exosomes	Purity of recovered exosomes	Biological samples used in the study	Ref.
Label-free (size-based)	Nano-DLD	0.012 $\mu\text{L h}^{-1}$	N/A	N/A	Human urine	48
	Acoustics	240 $\mu\text{L h}^{-1}$	82%	98.4%	Whole blood, cell culture medium	47
	Pinched-flow fractionation	1200 $\mu\text{L h}^{-1}$	N/A	N/A	Cell culture medium	45
	AF4	267–1333 $\mu\text{L h}^{-1}$	N/A	N/A	Cell culture medium	49
	Nanowire trapping	600 $\mu\text{L h}^{-1}$	10%	N/A	Mixture of BSA, liposome and beads	46
	Viscoelastic	200 $\mu\text{L h}^{-1}$	>80%	>90%	Cell culture medium, pure serum	31
	ExoTIC	5000 $\mu\text{L h}^{-1}$	>90%	N/A	Plasma, urine, lavage, cell culture medium	24
	Double filtration	2400 $\mu\text{L h}^{-1}$	92%	N/A	Cell culture medium, urine	25
	Exodisc-B/P	180–900 $\mu\text{L h}^{-1}$	76–88%	N/A	Whole blood, plasma, and cell culture medium	26
	FerroChip	60–180 $\mu\text{L h}^{-1}$	94.3%	87.9%	Cell culture medium and serum	This work
Label-based	iMER	240 $\mu\text{L h}^{-1}$	93%	N/A	Serum	44
	CD63-modified herringbone grooves	~800 $\mu\text{L h}^{-1}$	42–94%	N/A	Serum and cell culture medium	42
	CD41-modified mica surface	72 $\mu\text{L h}^{-1}$	N/A	N/A	Human plasma	41
	ExoChip	240 $\mu\text{L h}^{-1}$	N/A	N/A	Serum	17
	nPLEX	500 $\mu\text{L h}^{-1}$	N/A	N/A	Ascites fluid	43
	Nano-IMEX	3 $\mu\text{L h}^{-1}$	N/A	N/A	Diluted plasma	19

shows these two could be separated in the FerroChip as well. We also studied the theoretical size resolution of the FerroChip in separating nanoparticles and found the solution to be ~ 100 nm (ESI† Fig. S2).

In summary, we showed that the performance of FerroChip devices in separating 200 nm and 1000 nm particles met or exceeded the goals, including: (1) a complete 200 nm particle recovery rate of 100%; (2) a sample processing throughput of $3 \mu\text{L min}^{-1}$ ($180 \mu\text{L h}^{-1}$), and (3) a purity of 200 nm particles of 100% after separation. This performance enabled us to continue the device characterization using biological samples. We note that the particles used in this experiment had a very narrow size distribution, which led to a better-than-expected recovery rate and purity performance. When dealing with exosomes and other EVs in biological samples, their size polydispersity will lead to a decrease in the exosomal recovery rate and purity.

Validation of FerroChip for exosome-like nanoparticles separation using biological samples

We characterized the FerroChip's performance in separating exosomes from biological samples. The device geometry and operating parameters remained to be the same as in the previous section, except we further decreased the sample flow rate to $1 \mu\text{L min}^{-1}$ ($60 \mu\text{L per hour}$) to maximize the separation between exosomes and large EVs (see ESI† Fig. S1). This was determined after considering the polydispersity of sizes of exosomes and large EVs.

We first challenged the FerroChip with extracellular media collected from cultured breast cancer cell line MDA-MB-231 and characterized the exosomal recovery rate and purity of

the FerroChip. The EVs from this media were first enriched and separated into two groups based on their sizes using ultracentrifugation and a commercial kit (ExoQuick-TC, see Materials and methods). The first group contained large EVs (diameters: 200 nm to 1000 nm) that were stained with PKH 26 red fluorescence, and the second group contained small exosomes (diameters: 30 nm to 150 nm) that were stained with PKH 67 green fluorescence. Size profiles of the exosomes and large EVs were measured by atomic force microscopy and provided in the ESI† (Fig. S3). These two groups of EVs were then mixed together at a ratio of 1 to 1 (20 μL large EVs and 20 μL of exosomes resuspended in 1 mL of ferrofluids) and processed using the FerroChip at a sample flow rate of $1 \mu\text{L min}^{-1}$ and a sheath flow rate of $5 \mu\text{L min}^{-1}$ (Fig. 5a). After device processing, samples collected from middle and side outlets were analyzed for exosomal recovery and purity using two methods including super-resolution imaging and atomic force microscopy. In these analyses, we defined exosome-like nanoparticles to have diameters of 30–150 nm, and morphology and protein expressions consistent with other reports.⁵ Firstly, from a super-resolution imaging analysis of 730 particles, we found that the recovery rate of exosome-like particles, defined as the number of PKH 67 green fluorescent particles found in the side outlets over the number of PKH 67 green fluorescent particles found in all outlets of the FerroChip, was 92.6%, and the purity of recovered exosome-like particles, defined as the number of PKH 67 green fluorescent particles found in the side outlets over the sum of PKH 67 green fluorescent particles and PKH 26 red fluorescent particles found in the side outlets of the FerroChip, was 91.1% (Table 1). Secondly, the separation of the exosomes and large EVs was analyzed by atomic force




Fig. 4 Optimizations of the FerroChip for the separation of exosome-like nanoparticles (30–150 nm in diameter) from large extracellular vesicles (200–1000 nm in diameter). **a** Simulation results of the separation of 200 nm and 1000 nm polystyrene beads, at different flow rates (1–10 $\mu\text{L min}^{-1}$) in a 0.3% (v/v) ferrofluid. We considered 1–3 $\mu\text{L min}^{-1}$ to be optimal flow rates because they correspond to more than 400 μm separation distance in simulation. A 3 $\mu\text{L min}^{-1}$ optimal flow rate was chosen to separate 200 nm and 1000 nm polystyrene beads from each other. The ratio of particle flow and sheath flow was 1:5 (sample – 3 $\mu\text{L min}^{-1}$; sheath – 15 $\mu\text{L min}^{-1}$). Other simulation parameters included a ferrofluid concentration of 0.3%, and the same quadrupole magnet configuration in previous figures. Using these parameters, we simulated the distribution of 200 nm and 1000 nm beads at the outlets of the FerroChip. Particle trajectories from the simulation results predicted that the two differently sized particles could be completely separated. **b** Experimental images of the separation of a mixture of 200 nm (blue) and 1000 nm (red) polystyrene particles in the FerroChip. Fluorescent images taken at different locations along the microchannel showed that 200 nm particles (blue) were completely separated from 1000 nm particles (red). Both particles were collected for subsequent size characterization. Broad blue fluorescent signals across the channel at the location #3 were from the shade of the permanent magnets, not fluorescent particles. **c** Particle size distributions measured by dynamic light scattering (DLS) indicate a well-separated 1000 nm and 200 nm particles after FerroChip processing.

microscopy (AFM, representative images in ESI† Fig. S4). From an atomic force microscopic image analysis of 1581 particles, we found that the recovery rate of exosome-like particles with diameter less than 150 nm was 96%, and the purity was 84.7% (Table 1). The average recovery rate between these two characterization methods was 94.3% and the average purity was 87.9%. In addition, we used transmission electron microscopy (TEM) to characterize the diameter distribution of the separated exosome-like particles from the FerroChip. Fig. 5e shows that the diameter distribution of these separated exosome-like nanoparticles was 45 ± 26 nm, with a minimal diameter of 17 nm and a maximal diameter of 254 nm. This diameter range was consistent with established exosome diameters (30–150 nm).⁵ Conventional transmission electron microscopy with negative staining of the exosome output from the FerroChip also revealed that most separated exosomes had an artifactual cup-shaped morphology caused by shrinking (Fig. 5d), consistent with their established morphology in literature.⁵ Magnetic nanoparticles were removed from the exosome solution prior

to the TEM. This process, described in Materials and methods, did not appear to affect the morphology of the exosomes. We used Western blot analysis to examine the expression of exosomal protein markers in the samples collected from the side outlets and the middle outlet. We analyzed the expression of EV membrane tetraspanin CD63 and heat shock 70 kDa protein, HSP70. The sample collected from the side outlets showed a high expression of CD63 and HSP70 (Fig. 5c), confirming that the majority of exosomes were separated from the initial EV mixture into the side outlets. The EVs collected from the middle outlet showed a low level of CD63, indicating that a small quantity of exosomes also exited the device through the middle outlet. In addition to the separation of exosomes from the extracellular media, we also demonstrated an effective focusing effect on EVs in the FerroChip (see ESI† Fig. S5).

We further challenged the FerroChip with serum from a healthy human's blood. We aimed to show that the FerroChip could separate exosome-like nanoparticles from the serum. For this purpose, we processed 100 μL of serum




Fig. 5 Characterization of the FerroChip in separating exosome-like nanoparticles from biological samples. **a** We chose to use a $1 \mu\text{L min}^{-1}$ sample flow rate in order to separate exosome-like nanoparticles (30–150 nm in diameter) from extracellular media and human serum. This sample flow rate maximized the separation between exosome-like nanoparticles and large EVs (200–1000 nm in diameter). The ratio of sample flow and sheath flow was 1 : 5 (sample – $1 \mu\text{L min}^{-1}$; sheath – $5 \mu\text{L min}^{-1}$). Other device and operating parameters remained the same as in previous figures. **b** Super-resolution microscopic images of exosome-like nanoparticles (PKH 67 green fluorescence) and large EVs (PKH 26 red fluorescence) from the mixture (pre-separation), and the samples after FerroChip processing (large EVs and exosome outlets). A total of 730 particles were analyzed. **c** Western blot analysis of CD63 and HSP70 protein levels in large EVs and exosome-like nanoparticles that were processed by the FerroChip. **d** Transmission electron microscopy (TEM) images of exosome-like nanoparticles collected from the FerroChip. **e** Size distribution of separated exosome-like nanoparticles from TEM images ($n = 755$). **f** Immunofluorescence images of separated exosome-like nanoparticles from human serum. Three channels were used in immunofluorescent staining, including EpCAM (green), CD24 (red), and CD63 (cyan). **g** Venn diagram depicts the percentage of antibody presence on the surfaces of separated exosome-like nanoparticles ($n = 12\,000$) from human serum. EpCAM+ alone: 5%; CD24+ alone: 52%; CD63+ alone: 21%; EpCAM+ and CD24+: 4%; EpCAM+/CD63+: 2%; CD24+/CD63+: 14%; CD63+/CD24+/EpCAM+: 2%.

using the FerroChip at a sample flow rate of $1 \mu\text{L min}^{-1}$ and a sheath flow rate of $5 \mu\text{L min}^{-1}$. Exosomes separated from the FerroChip were investigated for their molecular signatures through the profiling of three antibodies. We

chose these antibodies based on prior studies, including CD63 that was particularly enriched on the surface of exosomes,^{5,30,40} and two putative cancer makers – epithelial cell adhesion molecule (EpCAM) and CD24.^{30,40} Both of

these cancer markers were not only detected in tumor-derived exosomes, but also in samples from healthy subjects.³⁰ We found that all three markers, CD63, EpCAM, and CD24 were detected in different combinations on the exosomes' surface from the human serum (Fig. 5f). Fig. 5g shows the Venn diagram depicting the percentage of each antibody's presence – EpCAM+ alone: 5%; CD24+ alone: 52%; CD63+ alone: 21%; EpCAM+/CD24+: 4%; EpCAM+/CD63+: 2%; CD24+/CD63+: 14%; CD63+/CD24+/EpCAM+: 2%. We also challenged the FerroChip with extracellular media from 7 cancer cell lines and investigated the antibody presence on the surfaces of recovered exosomes. The presence of these antibodies was heterogeneous across the cell lines (see ESI† Fig. S6). This information indicates that using a label-based exosome separation strategy will result in partial recovery and highlights a need for label-free strategies include the FerroChip.

Advantages and limitations of the FerroChip in separating exosome-like particles

We compared the FerroChip's performance of separating exosome-like nanoparticles to existing microfluidic methods. In doing so, we used three metrics including the sample-processing throughput, exosomal particle recovery rate, and purity of recovered exosomes. These three metrics were well established in the current literature of exosome separation.^{6,39} Through validations with both spike-in samples and biological samples using these operating parameters, the performance of the FerroChip in separating exosome-like particles was determined to have: (1) a recovery rate of 94.3%; (2) a purity of 87.9% in recovered particles; (3) a sample processing throughput of 60 $\mu\text{L h}^{-1}$. We compared these results to recently published microfluidic methods (Table 2) and found that the FerroChip had a better combined recovery rate and purity than existing methods.^{17,19,31,41–49}

On the other hand, the FerroChip presented in this study has the following limitations in separating exosome-like nanoparticles from biological fluids. Firstly, the sample processing throughput of the FerroChip was limited to $\sim 60 \mu\text{L h}^{-1}$. In the process of separating exosome-like particles from biological fluids, a sheath flow of ferrofluids was introduced along with the sample which resulted in a dilution of separated particles. Because of this limitation, FerroChip may be more suitable for applications such as blood liquid biopsy where the starting sample volume is usually small ($\sim 100 \mu\text{L}$) and the tumor-derived exosomes are abundant ($>10^9/\text{mL}$).^{20,30,39,50} Secondly, the impact of ferrofluids on the physiology of extracellular vesicles needs further studies. While in previous studies we have demonstrated the ferrofluids had minimally detrimental effects on mammalian cells,^{35,36,51} and in this study, the biophysical diameter, morphology, and common protein expressions appeared to be consistent with other reports, further molecular characterizations are still needed to assess the quality of the exosome-like particles from the FerroChip in order to adapt

this method for biological applications. Lastly, the FerroChip relies on the size-dependent ferrohydrodynamic force to separate larger EVs from smaller exosomes. As a result, it cannot distinguish exosomes from particulate impurities that have similar sizes in a biological fluid, which may lead to decreased purity of separated exosomes.

Conclusion

In this paper, we developed a new label-free ferrohydrodynamic method and its prototype devices (FerroChip) for a size-based separation of exosome-like particles from biological samples. FerroChip relies on particle ferrohydrodynamics of nanoscale extracellular vesicles in a biocompatible ferrofluid to separate smaller exosome-like nanoparticles from larger extracellular vesicles (EVs). Particle ferrohydrodynamics developed in the past was limited to micron-sized particle and cellular separations. Here we successfully demonstrated both in theory and with experiments that particle ferrohydrodynamics could be applied to exosome-like nanoparticles separation in microfluidic devices with $\sim 100 \text{ nm}$ size resolution. The developed FerroChip was used to separate exosome-like nanoparticles, defined as particles of 30–150 nm and having morphology and protein markers that were consistent exosomes, from biological fluids. FerroChip's separation had a recovery rate of 94.3% and a purity of 87.9% in recovered exosome-like nanoparticles. This is the first time that nanosized particles were separated *via* particle ferrohydrodynamics in microfluidic devices.

Materials and methods

Ferrohydrodynamic modeling in microfluidic devices

We adopted a previously developed analytical model in this study to simulate the trajectories of immersed nanoparticles/EVs in ferrofluids in a three-dimensional (3D) manner.^{35,51} This model provides a fast prediction of three-dimensional ferrohydrodynamic transport of nanoparticles and EVs inside a microfluidic channel coupled with quadruple configurations of permanent magnets. Trajectories of the nanoparticles/EVs in the FerroChip were obtained by (1) first computing the three-dimensional magnetic force *via* an experimentally verified and analytically computed distribution of magnetic fields as well as their gradients, together with a nonlinear Langevin magnetization model of the ferrofluid that considers ferrofluids to be a continuous medium, and the magnetic nanoparticles inside the ferrofluid to be non-interacting, (2) secondly computing the ferrohydrodynamic motion of diamagnetic nanoparticles/EVs through the governing equations of nanoparticles/EVs in laminar flow conditions, using analytical expressions of magnetic forces and hydrodynamic viscous drag forces. The script for this model was developed and solved in MATLAB (MathWorks Inc., Natick, MA).

Ferrofluids synthesis, characterization, and composition

Water-based ferrofluid with maghemite nanoparticles was synthesized by a chemical co-precipitation method following an established protocol.⁵¹ Transmission electron microscopy (TEM; FEI, Eindhoven, the Netherlands) were used to characterize the size and morphology of maghemite nanoparticles. The viscosity of ferrofluids was measured with a compact rheometer (Anton Paar, Ashland, VA) at room temperature. Magnetic properties (volume fraction of magnetic materials and saturation magnetization) of the ferrofluid were characterized using a vibrating sample magnetometer (VSM; MicroSense, Lowell, MA). The diameter distribution of the maghemite nanoparticles in the ferrofluid is 10.91 ± 4.86 nm. The surfactant on the nanoparticles is a graft copolymer (Atlox 4913, Croda, Inc., Edison, NJ). Ferrofluid was adjusted to biocompatible by changing the pH to 7 with sodium hydroxide and balancing the osmotic pressure with Hank's balanced salt solution (Thermo Fisher Scientific, Waltham, MA). The concentration of ferrofluid was measured to be 0.3% (v/v) and the corresponding viscosity of this ferrofluids was 1.68 mPa s at 23 °C.

Cell culture and extracellular vesicles preparation

Extracellular vesicles were prepared from cell lines: human breast cancer (MDA-MB-231, ATCC, Manassas, VA) and lung cancer (A549, ATCC, Manassas, VA). Cell lines were cultured following the manufacturer's recommended protocol. The culture medium was supplemented with 10% exosome-free FBS (Thermo Fisher Scientific, Waltham, MA). The extracellular vesicles were isolated from the cell culture supernatant. The collected supernatant was centrifuged at 500g for 5 minutes to remove cells. To collect extracellular vesicles smaller than 800 nm, the supernatant was processed by membrane filtration (800 nm pores, Pall Corporation), followed by adding 20% ExoQuick-TC reagent (System Biosciences, CA). The mixture was incubated overnight at 4 °C, followed by centrifugation at 1500g for 30 minutes. Extracellular vesicles were resuspended in 200 μ L using sterile 1 $\times$ PBS. To collect large extracellular vesicles (diameters: 200 nm to 1000 nm), the collected culture supernatant was processed by centrifugation at 12 000g for 90 minutes at room temperature. Large extracellular vesicles were collected by resuspending the pellet in 200 μ L 1 $\times$ PBS. Smaller exosomes (diameters: 30 nm to 150 nm) were obtained by mixing the remaining supernatant with 20% ExoQuick-TC reagent, following the manufacturer's protocol. The exosomes were resuspended in 200 μ L 1 $\times$ PBS. The extracellular vesicles (both large extracellular vesicles and small exosomes) were then fluorescently stained with PKH 67 or PKH 26 (Sigma-Aldrich, St. Louis, MO) following the manufacturer's protocol.

FerroChip fabrication and assembly

The microfluidic channel of the FerroChip contains a filtration channel and particle manipulation (focusing or

separation) channel. Using standard soft lithography techniques, the devices were made of polydimethylsiloxane (PDMS) with a channel height of 150 μ m, measured by a profilometer (Veeco Instruments, Chadds Ford, PA). The fabricated microchannel was placed in the quadrupole permanent magnet array and held in a custom-made aluminum manifold. Each magnet was 38.1 mm in length, 6.35 mm in both width and thickness, with a residual magnetic flux density of 1.48 T.

Microfluidic experiment setup and procedure

The FerroChip was first flushed by 70% ethanol for 10 minutes, followed by priming with 1 $\times$ PBS supplemented with 0.5% (w/v) bovine serum albumin (BSA) and 2 mM EDTA (Thermo Fisher Scientific, Waltham, MA) for 10 minutes with a flow rate of 100 μ L min⁻¹. Sample ferrofluids that contained polystyrene particles or extracellular vesicles were supplemented with 0.5% (w/v) BSA to prevent particle aggregation. Sample fluids and sheath fluids were injected into the microfluidic inlets using individually controlled syringe pumps (Chemxyx, Stafford, TX) at variable flow rates. The FerroChip was placed on the stage of an inverted microscope (Axio Observer, Carl Zeiss, Germany) for observation and recording. Images and videos of particles were obtained from a CCD camera (Carl Zeiss, Germany).

Removal of magnetic nanoparticles from exosomes

After FerroChip processing and before characterizations, the maghemite nanoparticles in ferrofluids could be removed by increasing the pH of the ferrofluid to 7.5–8 with sodium bicarbonate. Briefly, the sample was collected in an Eppendorf tube and the tube was placed into a customized magnet array. 0.1 M NaHCO₃ was added into the solution until its pH reached to 7.5–8. The solution was incubated for 3 hours at room temperature. The maghemite nanoparticles formed clusters and were attracted by the magnet array. Supernatant of the solution was removed, and the resulted solution was centrifuged at 1000g for 5 minutes to further remove nanoparticle clusters.

Extracellular vesicles characterization

Dynamic light scattering (DLS). Polystyrene submicron particles were measured by a Zetasizer Nano ZS Analyzer (Malvern Panalytical Ltd, United Kingdom). 5 μ L of the collected sample from FerroChip outlets was diluted with 20 mL filtered DI water and measured at room temperature.

Atomic force microscopy (AFM). Collected extracellular vesicles were imaged by a multimode-8 AFM (Bruker, Billerica, MA) using the tapping mode with the DNP-S10 probe.

Super-resolution microscopy. Collected extracellular vesicles were imaged by a Zeiss ELYRA S1 (SR-SIM) super-resolution microscope (Carl Zeiss, Germany).

Transmission electron microscopy (TEM). Collected extracellular vesicles were fixed with 2% paraformaldehyde for 10 min at room temperature and then dropped onto

electron microscope grids. After incubation for 20 min, the grids were transferred to a 50 μ L drop of 2.5% glutaraldehyde in sodium cacodylate buffer for 10 min. The grid was transferred to a 100 μ L drop of filtered distilled water and washed 3 times. After drying for 20 min, the extracellular vesicles were stained with 1% uranyl acetate for 1 min. Collected extracellular vesicles were imaged by JEOL JEM1011 (JOEL, Inc., Peabody, MA) transmission electron microscope (TEM) at 80 kV.

Western blot. Exosomes collected from the side channel of the FerroChip were lysed using RIPA buffer with protease inhibitor cocktail added. The protein concentration was quantified using a standard Bradford protein assay and 20 μ g of protein was loaded for each well. Laemmli buffer (with beta-mercaptoethanol) was added and the sample was heated at 95 °C for 5 minutes and chilled on ice before loading onto gel (Bio-Rad Laboratories, Hercules, CA). Standard SDS-PAGE electrophoresis was performed, and the protein lysates were transferred onto PVDF membrane (Santa Cruz Biotechnology, Inc., Dallas, TX). The membrane was then incubated overnight with exosome primary antibodies against CD63 and HSP70 (Santa Cruz Biotechnology, Inc., Dallas, TX) following incubation with goat-rabbit-HRP secondary antibody (Santa Cruz Biotechnology, Inc., Dallas, TX). Blot was incubated with Western ECL substrate (Bio-Rad Laboratories, Hercules, CA) to enhance the signal, and the blot was visualized with ChemiDoc MP Imaging System (Bio-Rad Laboratories, Hercules, CA).

Live subject statement

All experiments in this study were performed in compliance with the regulations of the United States Office for Human Research Protections, and the University of Georgia Human Subjects Office. Human whole blood from healthy subjects was purchased from a commercial vendor (Zen-Bio, Research Triangle, NC) without any identifying information. Blood samples are collected from an United States Food and Drug Administration regulated blood bank. All procedures, policies, forms and consents used in the donor screening, collection and manufacturing process are submitted to the FDA for review and approval through the prior approval supplement process described in 21 CFR 601.12(b). The blood sample used in this study, for which the authors or sponsors have no access to identifying information, do not meet the definition of human subjects (45 CFR 46) and are not regulated by the Office of Human Subjects Protections and would not be subject to institutional review board (IRB).

Blood sample preparation. The purchased blood sample was centrifuged at 3000g for 15 minutes to remove cells. The supernatant was mixed with a ferrofluid (volume fraction 0.6%) with a 1:1 ratio. Pluronic F-68 non-ionic surfactant (Thermo Fisher Scientific, Waltham, MA) was added before processing.

Immunofluorescence staining of exosomes. Isolated exosomes from human blood were plated onto a poly-L-lysine coated glass slide with a customized cell collection chamber

for 24 hours at 4 °C. The collected exosomes were fixed with 4% (w/v) PFA solution (Santa Cruz Biotechnology, Inc., Dallas, TX), following permeabilization with Triton X-100 buffer (Alfa Aesar, Haverhill, MA) for 10 minutes. The nonspecific binding sites of exosomes were blocked with a blocking reagent (Santa Cruz Biotechnology, Inc., Dallas, TX) before immunostaining with primary antibodies, including anti-EpCAM, anti-CD24, and anti-CD63 (Santa Cruz Biotechnology, Inc., Dallas, TX). The stained exosomes were washed with PBS and covered with mounting medium before imaging.

Authors' contribution

L. M. conceived the “particle ferrohydrodynamics” for nanoparticle manipulation and the FerroChip. L. M. and Y. L. designed the FerroChip and its research. Y. L. performed experiments. L. M. and Y. L. analyzed data. W. Z. aided with the experiments. Y. L., R. C., and L. M. performed the modeling and simulation. M. Z.-V. aided with the initial modeling. M. L. and L. K. aided with exosome characterization. Y. L. and L. M. wrote the manuscript with inputs from all the authors.

Conflicts of interest

The University of Georgia filed patent protection for FerroChip technology.

Acknowledgements

We thank Mr. Yongwook Kim and Professor Sergiy Minko for their help in AFM imaging. We thank the Biomedical Microscopy Core facility personnel for their help in super-resolution microscopy. We also thank the Georgia Electron Microscopy personnel for their help in the TEM imaging. This material is based upon work supported by the National Science Foundation under Grant No. 1150042, 1659525 and 1648035; by the National Institute of General Medical Sciences of the National Institutes of Health under Award No. R21GM104528; and the National Center for Advancing Translational Sciences of the National Institutes of Health under Award No. UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

- 1 J. Massague and A. C. Obenauf, *Nature*, 2016, **529**, 298–306.
- 2 A. W. Lambert, D. R. Pattabiraman and R. A. Weinberg, *Cell*, 2017, **168**, 670–691.
- 3 E. T. Roussos, J. S. Condeelis and A. Patsialou, *Nat. Rev. Cancer*, 2011, **11**, 573–587.
- 4 R. Xu, A. Rai, M. Chen, W. Suwakulsiri, D. W. Greening and R. J. Simpson, *Nat. Rev. Clin. Oncol.*, 2018, **15**, 617–638.
- 5 G. van Niel, G. D'Angelo and G. Raposo, *Nat. Rev. Mol. Cell Biol.*, 2018, **19**, 213–228.
- 6 J. C. Contreras-Naranjo, H. J. Wu and V. M. Ugaz, *Lab Chip*, 2017, **17**, 3558–3577.

- 7 M. Mathieu, L. Martin-Jaular, G. Lavieu and C. Thery, *Nat. Cell Biol.*, 2019, **21**, 9–17.
- 8 H. Peinado, H. Zhang, I. R. Matei, B. Costa-Silva, A. Hoshino, G. Rodrigues, B. Psaila, R. N. Kaplan, J. F. Bromberg, Y. Kang, M. J. Bissell, T. R. Cox, A. J. Giaccia, J. T. Erler, S. Hiratsuka, C. M. Ghajar and D. Lyden, *Nat. Rev. Cancer*, 2017, **17**, 302–317.
- 9 T. Celia-Terrassa and Y. Kang, *Nat. Cell Biol.*, 2018, **20**, 868–877.
- 10 B. Costa-Silva, N. M. Aiello, A. J. Ocean, S. Singh, H. Zhang, B. K. Thakur, A. Becker, A. Hoshino, M. T. Mark, H. Molina, J. Xiang, T. Zhang, T. M. Theilen, G. Garcia-Santos, C. Williams, Y. Ararso, Y. Huang, G. Rodrigues, T. L. Shen, K. J. Labori, I. M. Lothe, E. H. Kure, J. Hernandez, A. Doussot, S. H. Ebbesen, P. M. Grandgenett, M. A. Hollingsworth, M. Jain, K. Mallya, S. K. Batra, W. R. Jarnagin, R. E. Schwartz, I. Matei, H. Peinado, B. Z. Stanger, J. Bromberg and D. Lyden, *Nat. Cell Biol.*, 2015, **17**, 816–826.
- 11 B. A. Aguado, G. G. Bushnell, S. S. Rao, J. S. Jeruss and L. D. Shea, *Nat. Biomed. Eng.*, 2017, **1**, 1–12.
- 12 H. Peinado, M. Aleckovic, S. Lavotshkin, I. Matei, B. Costa-Silva, G. Moreno-Bueno, M. Hergueta-Redondo, C. Williams, G. Garcia-Santos, C. Ghajar, A. Nitadori-Hoshino, C. Hoffman, K. Badal, B. A. Garcia, M. K. Callahan, J. Yuan, V. R. Martins, J. Skog, R. N. Kaplan, M. S. Brady, J. D. Wolchok, P. B. Chapman, Y. Kang, J. Bromberg and D. Lyden, *Nat. Med.*, 2012, **18**, 883–891.
- 13 A. Hoshino, B. Costa-Silva, T. L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C. Williams, N. Soplop, K. Uryu, L. Pharmed, T. King, L. Bojmar, A. E. Davies, Y. Ararso, T. Zhang, H. Zhang, J. Hernandez, J. M. Weiss, V. D. Dumont-Cole, K. Kramer, L. H. Wexler, A. Narendran, G. K. Schwartz, J. H. Healey, P. Sandstrom, K. J. Labori, E. H. Kure, P. M. Grandgenett, M. A. Hollingsworth, M. de Sousa, S. Kaur, M. Jain, K. Mallya, S. K. Batra, W. R. Jarnagin, M. S. Brady, O. Fodstad, V. Muller, K. Pantel, A. J. Minn, M. J. Bissell, B. A. Garcia, Y. Kang, V. K. Rajasekhar, C. M. Ghajar, I. Matei, H. Peinado, J. Bromberg and D. Lyden, *Nature*, 2015, **527**, 329–335.
- 14 H. Shao, J. Chung, K. Lee, L. Balaj, C. Min, B. S. Carter, F. H. Hochberg, X. O. Breakefield, H. Lee and R. Weissleder, *Nat. Commun.*, 2015, **6**, 6999.
- 15 C. Chen, J. Skog, C. H. Hsu, R. T. Lessard, L. Balaj, T. Wurdinger, B. S. Carter, X. O. Breakefield, M. Toner and D. Irimia, *Lab Chip*, 2010, **10**, 505–511.
- 16 B. A. Ashcroft, J. de Sonnevile, Y. Yuana, S. Osanto, R. Bertina, M. E. Kuil and T. H. Oosterkamp, *Biomed. Microdevices*, 2012, **14**, 641–649.
- 17 S. S. Kanwar, C. J. Dunlay, D. M. Simeone and S. Nagrath, *Lab Chip*, 2014, **14**, 1891–1900.
- 18 H. Im, H. Shao, Y. I. Park, V. M. Peterson, C. M. Castro, R. Weissleder and H. Lee, *Nat. Biotechnol.*, 2014, **32**, 490–495.
- 19 P. Zhang, M. He and Y. Zeng, *Lab Chip*, 2016, **16**, 3033–3042.
- 20 Y. Wan, G. Cheng, X. Liu, S.-J. Hao, M. Nisic, C.-D. Zhu, Y.-Q. Xia, W.-Q. Li, Z.-G. Wang and W.-L. Zhang, *Nat. Biomed. Eng.*, 2017, **1**, 1–11.
- 21 B. H. Wunsch, J. T. Smith, S. M. Gifford, C. Wang, M. Brink, R. L. Bruce, R. H. Austin, G. Stolovitzky and Y. Astier, *Nat. Nanotechnol.*, 2016, **11**, 936–940.
- 22 S. Shin, D. Han, M. C. Park, J. Y. Mun, J. Choi, H. Chun, S. Kim and J. W. Hong, *Sci. Rep.*, 2017, **7**, 1–8.
- 23 H. Zhang and D. Lyden, *Nat. Protoc.*, 2019, **14**, 1027–1053.
- 24 F. Liu, O. Vermesh, V. Mani, T. J. Ge, S. J. Madsen, A. Sabour, E. C. Hsu, G. Gowrishankar, M. Kanada, J. V. Jokerst, R. G. Sierra, E. Chang, K. Lau, K. Sridhar, A. Bermudez, S. J. Pitteri, T. Stoyanova, R. Sinclair, V. S. Nair, S. S. Gambhir and U. Demirci, *ACS Nano*, 2017, **11**, 10712–10723.
- 25 L. G. Liang, M. Q. Kong, S. Zhou, Y. F. Sheng, P. Wang, T. Yu, F. Inci, W. P. Kuo, L. J. Li, U. Demirci and S. Wang, *Sci. Rep.*, 2017, **7**, 46224.
- 26 V. Sunkara, C. J. Kim, J. Park, H. K. Woo, D. Kim, H. K. Ha, M. H. Kim, Y. Son, J. R. Kim and Y. K. Cho, *Theranostics*, 2019, **9**, 1851–1863.
- 27 X. Dong, J. Chi, L. Zheng, B. Ma, Z. Li, S. Wang, C. Zhao and H. Liu, *Lab Chip*, 2019, **19**, 2897–2904.
- 28 H. K. Woo, V. Sunkara, J. Park, T. H. Kim, J. R. Han, C. J. Kim, H. I. Choi, Y. K. Kim and Y. K. Cho, *ACS Nano*, 2017, **11**, 1360–1370.
- 29 Z. Wang, H. J. Wu, D. Fine, J. Schmulen, Y. Hu, B. Godin, J. X. Zhang and X. Liu, *Lab Chip*, 2013, **13**, 2879–2882.
- 30 P. Zhang, X. Zhou, M. He, Y. Shang, A. L. Tetlow, A. K. Godwin and Y. Zeng, *Nat. Biomed. Eng.*, 2019, **3**, 438–451.
- 31 C. Liu, J. Guo, F. Tian, N. Yang, F. Yan, Y. Ding, J. Wei, G. Hu, G. Nie and J. Sun, *ACS Nano*, 2017, **11**, 6968–6976.
- 32 M. Wu, Y. Ouyang, Z. Wang, R. Zhang, P. H. Huang, C. Chen, H. Li, P. Li, D. Quinn, M. Dao, S. Suresh, Y. Sadosky and T. J. Huang, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, 10584–10589.
- 33 R. E. Rosensweig, *Ferrohydrodynamics*, Cambridge University Press, Cambridge, 1985.
- 34 W. Zhao, R. Cheng, J. R. Miller and L. Mao, *Adv. Funct. Mater.*, 2016, **26**, 3916–3932.
- 35 W. J. Zhao, R. Cheng, B. D. Jenkins, T. T. Zhu, N. E. Okonkwo, C. E. Jones, M. B. Davis, S. K. Kavuri, Z. L. Hao, C. Schroeder and L. D. Mao, *Lab Chip*, 2017, **17**, 3097–3111.
- 36 W. Zhao, Y. Liu, B. D. Jenkins, R. Cheng, B. N. Harris, W. Zhang, J. Xie, J. R. Murrow, J. Hodgson, M. Egan, A. Bankey, P. G. Nikolinakos, H. Y. Ali, K. Meichner, L. A. Newman, M. B. Davis and L. Mao, *Lab Chip*, 2019, **19**, 1860–1876.
- 37 R. M. Erb, H. S. Son, B. Samanta, V. M. Rotello and B. B. Yellen, *Nature*, 2009, **457**, 999–1002.
- 38 T. Zhu, R. Cheng, S. A. Lee, E. Rajaraman, M. A. Eiteman, T. D. Querec, E. R. Unger and L. Mao, *Microfluid. Nanofluid.*, 2012, **13**, 645–654.
- 39 M. He and Y. Zeng, *J. Lab. Autom.*, 2016, **21**, 599–608.
- 40 H. Im, H. Shao, Y. I. Park, V. M. Peterson, C. M. Castro, R. Weissleder and H. Lee, *Nat. Biotechnol.*, 2014, **32**, 490–495.
- 41 B. Ashcroft, J. De Sonnevile, Y. Yuana, S. Osanto, R. Bertina, M. Kuil and T. Oosterkamp, *Biomed. Microdevices*, 2012, **14**, 641–649.

- 42 C. Chen, J. Skog, C.-H. Hsu, R. T. Lessard, L. Balaj, T. Wurdinger, B. S. Carter, X. O. Breakefield, M. Toner and D. Irimia, *Lab Chip*, 2010, **10**, 505–511.
- 43 H. Im, H. Shao, Y. I. Park, V. M. Peterson, C. M. Castro, R. Weissleder and H. Lee, *Nat. Biotechnol.*, 2014, **32**, 490.
- 44 H. Shao, J. Chung, K. Lee, L. Balaj, C. Min, B. S. Carter, F. H. Hochberg, X. O. Breakefield, H. Lee and R. Weissleder, *Nat. Commun.*, 2015, **6**, 1–9.
- 45 S. Shin, D. Han, M. C. Park, J. Y. Mun, J. Choi, H. Chun, S. Kim and J. W. Hong, *Sci. Rep.*, 2017, **7**, 1–8.
- 46 Z. Wang, H.-J. Wu, D. Fine, J. Schmulen, Y. Hu, B. Godin, J. X. Zhang and X. Liu, *Lab Chip*, 2013, **13**, 2879–2882.
- 47 M. Wu, Y. Ouyang, Z. Wang, R. Zhang, P.-H. Huang, C. Chen, H. Li, P. Li, D. Quinn and M. Dao, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, 10584–10589.
- 48 B. H. Wunsch, J. T. Smith, S. M. Gifford, C. Wang, M. Brink, R. L. Bruce, R. H. Austin, G. Stolovitzky and Y. Astier, *Nat. Nanotechnol.*, 2016, **11**, 936.
- 49 H. Zhang and D. Lyden, *Nat. Protoc.*, 2019, **14**, 1027–1053.
- 50 H. Xu, C. Liao, P. Zuo, Z. Liu and B. C. Ye, *Anal. Chem.*, 2018, **90**, 13451–13458.
- 51 W. J. Zhao, R. Cheng, S. H. Lim, J. R. Miller, W. Z. Zhang, W. Tang, J. Xie and L. D. Mao, *Lab Chip*, 2017, **17**, 2243–2255.